🔥 We have been featured on Shark Tank India.Episode 13

🔥 We have been featured on Shark Tank India

logologo
Search anything
Ctrl+K
gift
arrow
WhatsApp Icon

Stock Summary and Key Metrics













Investment Checklist




























Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Ask AI

mockupmockup

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

View Standalone

Total Figures
QoQ Changes
Total Figures
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales482459450431433411390438485445
Expenses410397401384392399391420442414
Operating Profit716349484012-0.78184332
OPM %14.8213.6910.8711.079.302.93-0.204.008.887.08
Other Income4.43-5.85221.031.561.842.021.630.23-5.17
Interest8.11101214181618262526
Depreciation21242628292929303232
Profit Before Tax4623336.97-4.84-31-46-37-14-31
Tax %23.8531.2433.2073.89-106.828.279.180.8531.935.94
Net Profit3516221.82-10-28-41-36-9.21-29
EPS in Rs3.821.692.390.20-1.08-3.08-4.48-3.94-1.00-3.19

Consolidated Profit Loss (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales1,0971,0459681,1071,2421,5411,6691,8171,6651,671
Expenses9189078929831,0171,2131,3831,5731,5661,602
Operating Profit178138771232243272862449969
OPM %16.2713.237.9111.1318.0621.2517.1513.445.964.13
Other Income3.974.696.152.443.122.332.34216.457.05
Interest6.21242126221425386678
Depreciation6368727173797192114116
Profit Before Tax9148-9.3129132237193136-74-118
Tax %15.2614.9568.8215.5929.5134.5726.2228.57-4.811.59
Net Profit7741-2.90249315514297-78-116
EPS in Rs-0.312.6210.0816.7715.4210.51-8.44-12.61
Dividend Payout %19.1422.37-93.7511.4514.8513.3914.5914.27-2.37

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital18181818181818181818
Reserves5586336576426617518861,0101,0911,004
Borrowings125251233242203267257333672994
Other Liabilities239295330355389279325297363414
Total Liabilities9411,1971,2381,2581,2721,3151,4861,6582,1452,430
Fixed Assets374440489468590570555678954997
CWIP55911361855168122114125321
Investments160.020.020.020.020.020.022.468.711.46
Other Assets4966666136056316778098641,0571,111
Total Assets9411,1971,2381,2581,2721,3151,4861,6582,1452,430

Consolidated Cash Flows (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity112891231321238217417915795
Cash from Investing Activity-111-171-135-104-56-67-121-208-433-339
Cash from Financing Activity-1.62132-39-16-64-30-4423280241
Net Cash Flow-0.1150-51122.97-148.05-6.543.93-2.76

Documents

Presentations
Concalls
Reports
Presentations
iconiconicon

Investor Presentation

Q2 FY25

iconiconicon

Investor Presentation

Q4 FY24

Actions

Action Type




























































AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Ask AI

ai-corner-premiumai-corner-premium
ai-corner-premiumai-corner-premium

Frequently Asked Questions about Indoco Remedies Ltd

Indoco Remedies Ltd (INDOCO) is currently trading at 198.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Indoco Remedies Limited is a Mumbai-based pharmaceutical company engaged in manufacturing and marketing pharmaceutical formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company has showcased strong performance in its exports division, especially in emerging markets and its subsidiaries like FPP in the U.S. and Warren Remedies, with a notable increase in OTC business. Indoco has launched product extensions in India’s OTC market, including products like Sensodent DSP and Sensodent DPC, enhancing its presence in sensitivity protection and clean toothpaste segments. Indoco's API segment has seen growth, with significant developments like receiving the EIR for its Patalganga site from the USFDA, indicating strong regulatory compliance and operational standards. Despite challenges in its acute therapies segment impacting domestic sales, Indoco has achieved rank 21st in India's prescription audit, moving past major players like Pfizer.

Over the past 52 weeks, Indoco Remedies Ltd has traded between a low of ₹194.40 and a high of ₹348.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Indoco Remedies Ltd has a market capitalization of approximately 1,823.00. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Indoco Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -15.70 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,823.00 Cr, Indoco Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Indoco Remedies Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Indoco Remedies Ltd is -15.70. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.